DE60043149D1 - -myc zielgerichtete antisenseverbindungen - Google Patents
-myc zielgerichtete antisenseverbindungenInfo
- Publication number
- DE60043149D1 DE60043149D1 DE60043149T DE60043149T DE60043149D1 DE 60043149 D1 DE60043149 D1 DE 60043149D1 DE 60043149 T DE60043149 T DE 60043149T DE 60043149 T DE60043149 T DE 60043149T DE 60043149 D1 DE60043149 D1 DE 60043149D1
- Authority
- DE
- Germany
- Prior art keywords
- nuclease
- vivo
- oligomer
- antisense compounds
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3517—Marker; Tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11784699P | 1999-01-29 | 1999-01-29 | |
PCT/US2000/002331 WO2000044897A1 (en) | 1999-01-29 | 2000-01-29 | Method of treating restenosis by antisense targeting of c-myc |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60043149D1 true DE60043149D1 (de) | 2009-11-26 |
Family
ID=22375152
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60043149T Expired - Lifetime DE60043149D1 (de) | 1999-01-29 | 2000-01-29 | -myc zielgerichtete antisenseverbindungen |
Country Status (9)
Country | Link |
---|---|
US (1) | US6365351B1 (de) |
EP (2) | EP1173561A2 (de) |
JP (2) | JP2002535015A (de) |
KR (2) | KR20010102992A (de) |
AT (1) | ATE445700T1 (de) |
AU (2) | AU778057B2 (de) |
CA (2) | CA2360997A1 (de) |
DE (1) | DE60043149D1 (de) |
WO (2) | WO2000045167A2 (de) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010024783A1 (en) * | 1999-01-29 | 2001-09-27 | Avi Biopharma, Inc. | Non-invasive method for detecting target RNA |
CA2408011A1 (en) | 2000-05-04 | 2001-11-08 | Avi Biopharma, Inc. | Splice-region antisense composition and method |
CA2408746C (en) * | 2000-05-17 | 2010-09-21 | Patrick L. Iversen | Antisense phosporodiamidate morpholino oligonucleotide inhibition of cytochrome p450 to modulate drug pharmacokinetics |
AU2001286966B2 (en) * | 2000-08-30 | 2007-03-01 | Avi Biopharma, Inc. | Method for analysis of oligonucleotide analogs |
US7754238B2 (en) | 2002-05-03 | 2010-07-13 | Avi Biopharma, Inc. | Delivery of microparticle-conjugated drugs for inhibition of stenosis |
DK2351844T3 (da) | 2003-04-29 | 2014-09-22 | Sarepta Therapeutics Inc | Præparater til forøgelse af transport- og antisense-effektivitet af nukleinsyreanalog i celler |
AU2004263124B2 (en) * | 2003-08-07 | 2009-01-15 | Avi Biopharma, Inc. | Sense antiviral compound and method for treating ssRNA viral infection |
US20050222068A1 (en) * | 2003-10-23 | 2005-10-06 | Mourich Dan V | Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells |
US20050171044A1 (en) * | 2003-12-24 | 2005-08-04 | Stein David A. | Oligonucleotide compound and method for treating nidovirus infections |
CA2553104A1 (en) * | 2004-01-23 | 2005-08-11 | Avi Biopharma, Inc. | Antisense oligomers and methods for inducing immune tolerance and immunosuppression |
US20050288246A1 (en) | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
US7807816B2 (en) | 2004-06-28 | 2010-10-05 | University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
USRE48960E1 (en) | 2004-06-28 | 2022-03-08 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
ATE510914T1 (de) * | 2004-07-02 | 2011-06-15 | Avi Biopharma Inc | Antisinn antibakterielle verfahren und verbindungen |
US8129352B2 (en) | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
US8357664B2 (en) * | 2004-10-26 | 2013-01-22 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
US7524829B2 (en) * | 2004-11-01 | 2009-04-28 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
BRPI0519690A2 (pt) * | 2004-12-30 | 2009-03-03 | Todd M Hauser | composiÇÕes e mÉtodos para modular a expressço de genes usando oligonucleotÍdeos autoprotegidos |
ES2852549T3 (es) | 2005-02-09 | 2021-09-13 | Sarepta Therapeutics Inc | Composición antisentido para tratamiento de la atrofia muscular |
US20060240032A1 (en) * | 2005-03-31 | 2006-10-26 | Hinrichs David J | Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases |
US20060293268A1 (en) * | 2005-05-05 | 2006-12-28 | Rieder Aida E | Antisense antiviral compounds and methods for treating foot and mouth disease |
US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
US7790694B2 (en) * | 2005-07-13 | 2010-09-07 | Avi Biopharma Inc. | Antisense antibacterial method and compound |
US8329668B2 (en) * | 2005-09-08 | 2012-12-11 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
US8524676B2 (en) * | 2005-09-08 | 2013-09-03 | Sarepta Therapeutics, Inc. | Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds |
US8501704B2 (en) * | 2005-11-08 | 2013-08-06 | Sarepta Therapeutics, Inc. | Immunosuppression compound and treatment method |
WO2007103529A2 (en) * | 2006-03-07 | 2007-09-13 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating arenavirus infection |
US8785407B2 (en) * | 2006-05-10 | 2014-07-22 | Sarepta Therapeutics, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
DK2024499T3 (da) * | 2006-05-10 | 2018-01-29 | Sarepta Therapeutics Inc | Oligonukleotidanaloger med kationiske intersubunit-koblinger |
US20070265215A1 (en) * | 2006-05-11 | 2007-11-15 | Iversen Patrick L | Antisense restenosis composition and method |
ES2694726T3 (es) | 2007-06-29 | 2018-12-26 | Sarepta Therapeutics, Inc. | Conjugados peptídicos específicos de tejido y métodos |
US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
EP2350281B1 (de) | 2008-10-24 | 2014-05-14 | Sarepta Therapeutics, Inc. | Zusammensetzungen zum überspringen mehrerer exons bei dmd |
CA2746508A1 (en) * | 2008-12-17 | 2010-07-15 | Avi Biopharma, Inc. | Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis |
US20110269665A1 (en) | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
HUE040445T2 (hu) | 2009-11-12 | 2019-03-28 | Univ Western Australia | Antiszensz molekulák és eljárások betegségek kezelésére |
WO2011060320A1 (en) | 2009-11-13 | 2011-05-19 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
CA2799501C (en) | 2010-05-28 | 2022-02-15 | Sarepta Therapeutics, Inc. | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups |
US8198429B2 (en) | 2010-08-09 | 2012-06-12 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
US10017763B2 (en) | 2010-09-03 | 2018-07-10 | Sarepta Therapeutics, Inc. | dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups |
US9161948B2 (en) | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
JP5850519B2 (ja) * | 2011-05-09 | 2016-02-03 | ネッパジーン株式会社 | モルフォリノ搭載バブルリポソームを有効成分としてなる筋ジストロフィー治療薬 |
US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
EA035030B1 (ru) | 2011-11-18 | 2020-04-20 | Сарепта Терапьютикс, Инк. | Модифицированные морфолиновые аналоги олигонуклеотидов |
BR122020016865B1 (pt) | 2013-03-14 | 2022-12-27 | Sarepta Therapeutics, Inc. | Oligonucleotídeo antisenso, composição farmacêutica compreendendo o mesmo e uso da dita composição para o tratamento de distrofia muscular de duchenne (dmd) |
CA2906812A1 (en) | 2013-03-15 | 2014-09-18 | Sarepta Therapeutics, Inc. | Improved compositions for treating muscular dystrophy |
MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
EP3302489A4 (de) | 2015-06-04 | 2019-02-06 | Sarepta Therapeutics, Inc. | Verfahren und verbindungen zur behandlung von krankheiten und leiden im zusammenhang mit lymphozyten |
HUE059843T2 (hu) | 2016-12-19 | 2023-01-28 | Sarepta Therapeutics Inc | Exonátugró oligomerkonjugátumok izomdisztrófiára |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5034506A (en) * | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
DE3650699T2 (de) * | 1985-03-15 | 1999-04-15 | Antivirals Inc | Immunotestmittel für Polynukleotid und Verfahren |
US5521063A (en) * | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
US5506337A (en) * | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
US5235033A (en) * | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
US5378841A (en) * | 1989-12-20 | 1995-01-03 | Antivirals Inc. | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
JP3398378B2 (ja) * | 1989-12-20 | 2003-04-21 | アンチビラルス・インコーポレイテツド | リン含有キラルインターサブユニットリンケージを有する非電荷モルホリノ―基体ポリマー |
US5843684A (en) | 1990-06-27 | 1998-12-01 | The Trustees Of Princeton University | Method for detecting pre-cancerous or cancerous cells using P90 antibodies or probes |
US5756476A (en) * | 1992-01-14 | 1998-05-26 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of cell proliferation using antisense oligonucleotides |
HU220969B1 (hu) * | 1993-01-07 | 2002-07-29 | Thomas Jefferson University | A C-MYC-re specifikus antiszensz oligonukleotid alkalmazása simaizomsejtek proliferációjának szabályozásában |
US6323184B1 (en) * | 1993-10-15 | 2001-11-27 | Thomas Jefferson University | Arteriovenous and venous graft treatments: methods and compositions |
WO1995010305A1 (en) * | 1993-10-15 | 1995-04-20 | Thomas Jefferson University | Inhibition of extracellular matrix synthesis by antisense compounds directed to nuclear proto-oncogenes |
US5656612A (en) | 1994-05-31 | 1997-08-12 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
US5981731A (en) | 1994-05-31 | 1999-11-09 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of B-raf gene expression |
US5563255A (en) * | 1994-05-31 | 1996-10-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
CA2126952C (en) * | 1994-06-28 | 2010-12-14 | Sithian Pandian | Probe, kit, and method of amplification for increasing the sensitivity of nucleic acid hybridization assays |
CA2139070C (en) * | 1994-12-23 | 2010-03-30 | Burton W. Blais | Method for enhancing detection ability of nucleic acid assays employing polymerase chain reaction |
DE19502912A1 (de) * | 1995-01-31 | 1996-08-01 | Hoechst Ag | G-Cap Stabilisierte Oligonucleotide |
US5877309A (en) * | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
-
2000
- 2000-01-28 EP EP00911675A patent/EP1173561A2/de not_active Withdrawn
- 2000-01-28 CA CA002360997A patent/CA2360997A1/en not_active Abandoned
- 2000-01-28 WO PCT/US2000/002475 patent/WO2000045167A2/en not_active Application Discontinuation
- 2000-01-28 AU AU33537/00A patent/AU778057B2/en not_active Ceased
- 2000-01-28 KR KR1020017009235A patent/KR20010102992A/ko not_active Application Discontinuation
- 2000-01-28 JP JP2000596368A patent/JP2002535015A/ja active Pending
- 2000-01-28 US US09/493,494 patent/US6365351B1/en not_active Expired - Lifetime
- 2000-01-29 CA CA2359317A patent/CA2359317C/en not_active Expired - Lifetime
- 2000-01-29 KR KR1020017009506A patent/KR100684547B1/ko active IP Right Grant
- 2000-01-29 AT AT00905838T patent/ATE445700T1/de not_active IP Right Cessation
- 2000-01-29 WO PCT/US2000/002331 patent/WO2000044897A1/en active IP Right Grant
- 2000-01-29 DE DE60043149T patent/DE60043149D1/de not_active Expired - Lifetime
- 2000-01-29 AU AU27459/00A patent/AU779128B2/en not_active Expired
- 2000-01-29 JP JP2000596139A patent/JP2002537230A/ja active Pending
- 2000-01-29 EP EP00905838A patent/EP1153129B1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP1153129A1 (de) | 2001-11-14 |
WO2000045167A2 (en) | 2000-08-03 |
EP1153129B1 (de) | 2009-10-14 |
CA2359317C (en) | 2014-01-21 |
KR100684547B1 (ko) | 2007-02-20 |
WO2000044897A1 (en) | 2000-08-03 |
ATE445700T1 (de) | 2009-10-15 |
AU3353700A (en) | 2000-08-18 |
JP2002537230A (ja) | 2002-11-05 |
AU778057B2 (en) | 2004-11-11 |
US6365351B1 (en) | 2002-04-02 |
KR20010101760A (ko) | 2001-11-14 |
JP2002535015A (ja) | 2002-10-22 |
EP1173561A2 (de) | 2002-01-23 |
WO2000045167A3 (en) | 2000-12-21 |
AU2745900A (en) | 2000-08-18 |
AU779128B2 (en) | 2005-01-06 |
CA2360997A1 (en) | 2000-08-03 |
CA2359317A1 (en) | 2000-08-03 |
KR20010102992A (ko) | 2001-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60043149D1 (de) | -myc zielgerichtete antisenseverbindungen | |
US5656612A (en) | Antisense oligonucleotide modulation of raf gene expression | |
Folini et al. | Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells | |
Folini et al. | Inhibition of telomerase activity by a hammerhead ribozyme targeting the RNA component of telomerase in human melanoma cells | |
EP0763052B1 (de) | ANTISENSE OLIGONUKLEOTIDMODULATION DER raf GENEXPRESSION | |
Asai et al. | A novel telomerase template antagonist (GRN163) as a potential anticancer agent | |
ES2377327T3 (es) | Compuestos antisentido | |
KR101931089B1 (ko) | Pcsk9 를 표적화하는 안티센스 올리고머 및 접합체 | |
CA2221448C (en) | Antisense oligonucleotide modulation of raf gene expression | |
CA2526893A1 (en) | Inhibition of the expression of huntingtin gene | |
US6358932B1 (en) | Antisense oligonucleotide inhibition of raf gene expression | |
WO2011008982A1 (en) | Treatment of neurological disorders | |
US9062121B2 (en) | Stabilized STAT3 decoy oligonucleotides and uses therefore | |
Rajeev et al. | High-affinity peptide nucleic acid oligomers containing tricyclic cytosine analogues | |
WO2023011360A1 (zh) | 一种增强核酸药物缓释能力的方法 | |
EP3532617B1 (de) | Antisense-oligonukleotide | |
Coulson et al. | A nonantisense sequence-selective effect of a phosphorothioate oligodeoxynucleotide directed against the epidermal growth factor receptor in A431 cells. | |
DK1175489T3 (da) | Oligonukleotider indeholdende en antisense-sekvens stabiliseret af en sekundær struktur og farmaceutiske præparater indeholdende disse oligonukleotider | |
Kim et al. | Therapeutic efficacy of modified anti-miR21 in metastatic prostate cancer | |
Vidalin et al. | In vitro inhibition of hepatitis C virus gene expression by chemically modified antisense oligodeoxynucleotides | |
KR100199247B1 (ko) | Ras 유전자의 안티센스 올리고뉴클레오티드 저해 | |
KR100211178B1 (ko) | 라프유전자 발현의 안티센스 올리고뉴클레오티드 조절 | |
AU2003258183A1 (en) | Use of antisense oligonucleotides to inhibit the expression of akt-1 | |
Schindler et al. | Human telomerase reverse transcriptase antisense treatment downregulates the viability of prostate cancer cells in vitro | |
KR20210091732A (ko) | Mir-10b 활성을 조정하는 마이크로rna 및 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |